Table 2 Associations between vascular risk factors at baseline and progression measured by annual change in CDR-SB

Beta

95% CI

p

R²

 Hypertension

−0.049

(−0.617, 0.519)

0.87

0.04

 Hypercholesterolemia

0.262

(−0.153, 0.676)

0.22

0.05

 Diabetes mellitus

0.128

(−0.592, 0.848)

0.73

0.04

 Overweight (BMI ≥25)

− 0.391

(− 0.840, 0.059)

0.09

0.04

 Smoking (current)

0.050

(−0.677, 0.778)

0.89

0.04

  ≥ 2 VRFs

0.121

(−0.370, 0.612)

0.63

0.03

  ≥ 3 VRFs

−0.371

(−0.889, 0.147)

0.16

0.04

 Framingham Stroke Risk Profile, women*

−0.297

(−2.769, 2.175)

0.81

0.00

 Framingham Stroke Risk Profile, men*

0.930

(−1.638, 3498)

0.47

0.01

 ApoE ε4 carrier

0.384

(−0.069, 0.836)

0.10

0.06

 Heart disease

0.196

(−0.380, 0.771)

0.50

0.04

 Atrial fibrillation

−0.159

(0.902, 0.583)

0.67

0.04

 Peripheral vascular disease

0.512

(−0.834, 1.858)

0.46

0.04

 Cerebrovascular event (stroke and/or TIA)

−0.315

(−0.896, 0.265)

0.29

0.04

 Cortical infarcts (1 = cortical infarcts, 0 = no cortical infarcts)

0.707

(−0.518, 1.932)

0.26

0.04

 Lacunes (1 = ≥1 lacune on MRI, 0 = no lacunes)

−0.177

(−0.867, 0.514)

0.61

0.04

 Infarcts (cortical and/or lacunes)

0.038

(−0.611, 0.687)

0.91

0.03

 White matter hyperintensities Fazekas 3

−0.291

(−0.872, 0.290)

0.32

0.04

 White matter hyperintensities Fazekas 2 or 3

−0.207

(−0.776, 0.362)

0.47

0.04

 Infarcts and/or WMH Fazekas 3

−0.079

(−0.625, 0.468)

0.78

0.03

 Infarcts and/or WMH Fazekas 2 or 3

−0.298

(−0.872, 0.277)

0.31

0.04

 MTA (mean of right and left side)

0.036

(−0.262, 0.334)

0.81

0.04